Shire announces new $400 million biologics plant and 400 new jobs in Ireland

pharmafile | April 18, 2016 | News story | Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals 

Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver 400 new jobs in Co. Meath.

Over the next four years, the company will expand its global biotechnology manufacturing capacity in the country to meet the growing demand for its products as well as to facilitate its current pipeline. The 120 acre site at Piercetown will also provide an additional 700 jobs during construction, which is expected to be finished by 2019.

Flemming Ornskov, chief executive officer at Shire, comments: “Increasing our biologics manufacturing capability is fundamental to achieving our ambition of becoming the world’s leading biotechnology company focused on rare diseases and other speciality conditions. The expansion will enable us to meet increasing product demands, support our pipeline and, ultimately, help more patients. We are delighted to be expanding our operations in Ireland, where we have strong, existing relationships.”

Senior VP of technical operations at Shire, Tim Kelly, adds: “The expansion supports our manufacturing strategy to develop and provide innovative speciality medicines for patients… We already have a strong team on the ground in Ireland and believe that it is the right location for us to build a new state of the art facility which will complement our existing manufacturing operations in the US.”

Sean Murray

Related Content


Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …

Astellas plans to invest over €330m in new facility in Ireland

Astellas Pharma has announced that it is preparing to submit a planning application to build …

CellCentric announces $25m investment from Pfizer

UK-based biotechnology company CellCentric has announced a strategic investment from Pfizer including $25m to finance …

Latest content